Company Overview and News

43
Catalyst Watch: Adamis Faces A Big FDA Decision This Week On Symjepi Jr.

5h seekingalpha - 1
Symjepi Jr., the low-dose version of Adamis’ Symjepi epinephrine prefilled syringe, faces a PDUFA decision expected Thursday, Sep. 27; approval is broadly anticipated, given the adult variant has been approved.
NVS ADMP

41
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock

9h zacks
Investors in Adamis Pharmaceuticals Corporation (ADMP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $5.00 Call had some of the highest implied volatility of all equity options today.
ADMP

41
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

9h zacks
Investors in Adamis Pharmaceuticals Corporation (ADMP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 21, 2018 $5.00 Call had some of the highest implied volatility of all equity options today.
ADMP

45
Adamis Offers A Rare Business Update

2018-08-31 seekingalpha - 3
On Aug. 27, Adamis issued a business update, an unusual occurrence for a company that has proven wary of disclosure and investor communications.
NVS ADMP

43
Adamis Pharmaceuticals Provides Business Update

2018-08-27 globenewswire - 2
SAN DIEGO, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update.
ADMP

49
Sears, Exelixis Fall into Tuesday’s 52-Week Low Club

2018-08-21 247wallst - 1
August 21, 2018: Here are four stocks trading with heavy volume among 40 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers led decliners by about 1.82 to 1, and on the Nasdaq, advancers led decliners by about 2.69 to 1.
SHLD EXEL SEAC SHLDW ADMP

46
Adamis Looks Cheap Despite Serious Leadership Concerns

2018-08-19 seekingalpha - 4
Adamis' shares fell sharply Aug. 16-17 on the news that generic drug giant Teva had won approval for its generic EpiPen competitor.
NVS ADMP

60
FDA approves first rival generic EpiPen, sending Teva shares up 6%

2018-08-16 marketwatch - 3
Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. TEVA, +6.07% surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector.
TEVJF TEVA TEVVF ADMP

41
Loma Negra Compania Sees Hammer Chart Pattern: Time to Buy?

2018-08-13 zacks
Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because LOMA recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
REI LOMA ADMP

41
One Stop Systems Sees Hammer Chart Pattern: Time to Buy?

2018-08-13 zacks
One Stop Systems, Inc. (OSS - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OSS recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
OSS REI ADMP

44
athenahealth Sees Hammer Chart Pattern: Time to Buy?

2018-08-13 zacks - 1
athenahealth, Inc. (ATHN - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ATHN recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
REI ATHN ADMP

42
Is Clearfield (CLFD) Stock Outpacing Its Computer and Technology Peers This Year?

2018-08-11 zacks - 1
Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. Is Clearfield (CLFD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Computer and Technology peers, we might be able to answer that question.
REI CLFD ADMP

41
Has Actuant (ATU) Outpaced Other Industrial Products Stocks This Year?

2018-08-11 zacks
The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Actuant (ATU - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ATU and the rest of the Industrial Products group's stocks.
ATU REI ADMP

48
PLAY vs. SBUX: Which Stock Should Value Investors Buy Now?

2018-08-11 zacks
Investors interested in Retail - Restaurants stocks are likely familiar with Dave & Buster's (PLAY - Free Report) and Starbucks (SBUX - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
REI SBUX ADMP

ADMP : Adamis Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Adamis Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. the company is currently developing several products in the allergy and respiratory markets, including its Epinephrine Injection pre-filled syringe, or PFS, product for use in the emergency treatment of acute allergic reactions, including anaphylaxis; albuterol (APC-2000) and fluticasone (APC-4000) Dry Powder Inhaler, or DPI, products for the treatment of bronchospasm and asthma, respectively; and a steroid hydrofluoroalkane, or HFA metered dose inhaler product (APC-1000) for the treatment of asthma. Adamis's goal is to create low cost therapeutic alternatives to existing treatments. Consistent across all specialty pharmaceuticals product lines, the company intend to submit Section 505(b)(2) New Drug Applications, or NDAs, or Section 505(j) Abbreviated New Drug Applications, or ANDAs, to the U.S. Food and Drug ...

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

4h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

CUSIP: 00547W208